Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Volume

<< Previous

Bullboard Posts

Next >>

Comment by venture009on May 10, 2023 11:55pm

237 Views

Post# 35442376

RE:RE:Volume

Westcoast,
Management are certainly putting a lot of emphasis on ASCO so it better be good. Then we'll see how excited the market reaction is. As Geneman said if pela turns tumors from cold to hot then the price will look after itself. Otherwise the proverbal pin will hit the balloon once again.
ONCY's release today was another example of the management being able to convince the shareholders to go along with their recommendations and fleece the shareholders once again. I wish they were as successful at convincing a partner or BP to buy them.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing